Cardiac Bio Implant Devices Market Size, Share Report, Analysis, Trends, Growth 2032

The global Cardiac Bio Implant Devices market size accrued earnings worth approximately USD 48.80 Billion in 2023 and is predicted to gain revenue of about USD 115.25 Billion by 2032, is set to record a CAGR of nearly 10.02% over the period from 2024 to 2032.

Request Free Sample

Global Cardiac Bio Implant Devices Market: Overview

Cardiac diseases are a class of conditions that involve blood vessels and heart. Most common types of cardiac diseases are coronary artery disease, arrhythmia, congestive heart failure, peripheral artery disease, stroke, high blood pressure, cardiac arrest. Symptoms of the cardiac disease include shortness of breath, chest pain, chest discomfort, pain, numbness, pain in the neck, jaw, throat, upper abdomen or back. Risk factors associated with cardiac disease involve high blood pressure [hypertension], smoking, high cholesterol, stress, drinking too much alcohol.

Cardiac bio-implant devices are the medical devices used for the treatment of cardiac diseases. Cardiac bio-implants have special compatibility with body tissues or blood to assure that the device is not rejected due to adverse thrombogenic or hemodynamic blood responses. The distinct implantable cardiovascular devices usable are pacemakers, heart valves, cardioverter defibrillators, left the ventricular assisted device, artificial hearts, vascular grafts, and stents.

Request Free Sample

Global Cardiac Bio Implant Devices Market: Growth Factors

The rise in the aging population has increased the use of cardiac bio implant devices recently. The key factors driving the growth of global cardiac bio implant devices market are product innovation in cardiac implantable devices, rise in healthcare infrastructure of developing nations, changing lifestyle leading to increasing in cardiovascular diseases, increasing health awareness, healthcare expenditure rise, launch of brand new and innovative cardiac products such as subcutaneous defibrillators (S-ICDs) and leadless pacemakers. Stringent regulatory requirements, complications associated with the use of implants, high cost are some of the factors, restraining the growth of the global cardiac bio-implant devices market to some extent.

The market for Cardiac Bio-Implant Devices comprises pacemakers, ICDs, and Cardiac Resynchronization Therapy (CRT). The expansion of the CRT market is influenced by various factors, including a high prevalence of coronary heart disease, an increase in heart failure and other cardiac issues, and a growing global population of elderly individuals. The worldwide adoption of CRT is being propelled by unhealthy lifestyles and cardiovascular risk factors such as diabetes, obesity, poor diets, sedentary behavior, and excessive alcohol consumption, which also contribute to the rising incidence of heart disease. The Asia-Pacific region is expected to witness a significant aging population by 2050, leading to an increased prevalence of cardiovascular disease and a greater demand for CRT.

The market is expected to experience growth due to the introduction of new products over the projected period. For instance, in February 2021, Medtronic introduced the TYRX Absorbable Antibacterial Envelope. This unique, single-use envelope possesses antibacterial properties and is designed to support cardiac implantable electronic devices or implanted neurostimulators.

Cardiac Bio Implant Devices Market: Report Scope

Global Cardiac Bio Implant Devices Market: Segmentation

The global cardiac bio-implant devices market is segmented into structural cardiac implants, stents and related implants, a pacing device, disease conditions, and procedures. The structural cardiac implants segment comprises ventricular-assist devices, heart valves, and accessories, insertable loop recorders/implantable heart monitors. Whereas, the stents and related implants segment includes stent-related implants, coronary stents, peripheral stents. The segment of pacing devices includes implantable cardiac pacemakers (ICPs), implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy devices (CRTs) and pacing accessories.

In terms of disease conditions, the market is categorized into Arrhythmias, Myocardial Ischemia, Acute Myocardial Infarction and others. By procedure, it has been subclassified into Angioplasty, Heart Valve Repair or Replacement, Open heart surgery, Minimally Invasive Heart Surgery, Cardiac Resynchronization Therapy (CRT) and others.

Global Cardiac Bio Implant Devices Market: Regional Analysis

Advancing healthcare sector and progress in infrastructure would lead to an expansion in cardiac bio-implant devices market in Asia. Asia is anticipated to show high development rates in the next five years in the global cardiac bio-implant devices market. India and China have been expected to be the fastest growing cardiac bio-implant devices markets in the Asia-Pacific region. North America rules the global market for cardiac bio-implant devices due to lifestyle associated diseases and a plentiful number of aging population. Some of the major driving reasons for this market in arising countries are an enormous pool of patients, gain in government funding and risen healthcare expenditure. 

Global Cardiac Bio Implant Devices Market: Competitive Players

Some of the major companies operating in the global cardiac bio-implant devices market are

• Abbott
• Edwards Lifesciences Corporation
• Johnson & Johnson Services Inc.
• LivaNova PLC
• Medtronic
• Boston Scientific Corporation
• MicroPort Scientific Corporation
• Mayo Foundation for Medical Education and Research (MFMER)
• ClearPoint Neuro Inc.
• Imricor
• BIOTRONIK
• Bentley
• Elestim-Cardio
• QualiMed
• MEDICO S.p.A.
• Lepu Medical Technology(Beijing)Co.,Ltd.
• W. L. Gore & Associates Inc.
• LifeNet Health among other.

Global Cardiac Bio Implant Devices Market: Segment Analysis

By Product

• Structural Cardiac Implants
• Stents and Related Implants
• A Pacing Device

By Disease

• Myocardial Ischemia
• Acute Myocardial Infarction
• Arrhythmias
• Congestive Heart Failure (CHF)
• Angina Pectoris (AP)
• Cardiomyopathy
• Aortic Aneurism
• Others

By Procedure

• Angioplasty
• Heart Valve Repair or Replacement
• Open Heart Surgery
• Minimally Invasive Heart Surgery
• Cardiac Resynchronization Therapy (CRT)
• Others

By Region

• North America
  • The U.S.
• Europe
  • The UK
  • France
  • Germany
• The Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.